Targeted Therapeutics in Melanoma
Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | , |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
New York, NY :
Springer New York,
2012.
|
| Σειρά: | Current Clinical Oncology
|
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Molecular targets and subtypes in melanoma
- Melanoma genomics
- Predictive biomarkers as a guide to future therapy selection in melanoma
- KIT as a therapeutic target for melanoma
- Targeted inhibition of B-Raf
- The notch and B-catenin pathways
- STAT3 and Src signaling in melanoma
- Targeting the mTOR, PI3K and AKT pathways in melanoma
- Targeting apoptotic pathways in melanoma
- Anti-angiogenesis therapy in melanoma
- Melanoma antigens recognized by T lymphocytes
- Melanoma vaccines
- Adoptive cell therapy for the treatment of metastatic melanoma
- Anti-CTLA-4 monolonal antibodies
- Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies
- Treatment of melanoma with agonist immune co-stimulatory agents
- Novel cytokines for immunotherapy of melanoma
- Modulating the tumor microenvironment.
